Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.71 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599480 | 0.85 | MCL1 (0.76) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL401039 | 0.83 | MCL1 (0.73) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL117186 | 0.83 | MCL1 (1.00) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL2322980 | 0.81 | MCL1 (0.71) | MCL1SLC9A1MAPTDAOMEN1 | |
| Hydrochloric Acid SCHEMBL8600262 | 0.81 | MCL1 (0.96) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL2323444 | 0.81 | MCL1 (0.71) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL10350688 | 0.80 | MCL1 (0.69) | MCL1SLC9A1MAPTDAOMEN1 | |
| Hydrochloric Acid SCHEMBL28264080 | 0.80 | MCL1 (0.69) | MCL1SLC9A1MAPTDAOMEN1 | |
| Potassium Ion SCHEMBL15876031 | 0.80 | MCL1 (0.69) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL27467673 | 0.80 | MCL1 (0.74) | MCL1SLC9A1MAPTDAOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1020446-B1 | NAPHTHALIMIDOBENZAMIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6300331-B1 | DRUGS AS ANTITUMOR AGENTS OR ANTICARCINOGENIC AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1020446-A1 | NAPHTHALIMIDOBENZAMIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | MCL1 2770/4885SLC9A1 2930/4885MAPT 4754/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | MCL1 2086/4885SLC9A1 3148/4885MAPT 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.